TherapeuticsMD Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 121/158 in the Pharmaceuticals industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
TherapeuticsMD Inc's Score
Industry at a Glance
Industry Ranking
121 / 158
Overall Ranking
366 / 4582
Industry
Pharmaceuticals
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
0
analysts
--
Current Rating
--
Target Price
--
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
TherapeuticsMD Inc Highlights
StrengthsRisks
TherapeuticsMD, Inc. is a pharmaceutical royalty company, which primarily collects royalties from its licensees. It receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. It granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).
Growing
The company is in a growing phase, with the latest annual income totaling USD 1.76M.
Overvalued
The company’s latest PE is 64.96, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 3.26M shares, decreasing 9.65% quarter-over-quarter.
TherapeuticsMD, Inc. is a pharmaceutical royalty company, which primarily collects royalties from its licensees. It receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. It granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).
Ticker SymbolTXMD
CompanyTherapeuticsMD Inc
CEOWalker (Marlan D)
Websitehttps://www.therapeuticsmd.com/
FAQs
What is the current price of TherapeuticsMD Inc (TXMD)?
The current price of TherapeuticsMD Inc (TXMD) is 1.700.
What is the symbol of TherapeuticsMD Inc?
The ticker symbol of TherapeuticsMD Inc is TXMD.
What is the 52-week high of TherapeuticsMD Inc?
The 52-week high of TherapeuticsMD Inc is 2.440.
What is the 52-week low of TherapeuticsMD Inc?
The 52-week low of TherapeuticsMD Inc is 0.700.
What is the market capitalization of TherapeuticsMD Inc?
The market capitalization of TherapeuticsMD Inc is 19.68M.
What is the net income of TherapeuticsMD Inc?
The net income of TherapeuticsMD Inc is -2.18M.
Is TherapeuticsMD Inc (TXMD) currently rated as Buy, Hold, or Sell?
According to analysts, TherapeuticsMD Inc (TXMD) has an overall rating of --, with a price target of --.
What is the Earnings Per Share (EPS TTM) of TherapeuticsMD Inc (TXMD)?
The Earnings Per Share (EPS TTM) of TherapeuticsMD Inc (TXMD) is 0.026.